Roivant Sciences (ROIV) EBT (2020 - 2026)

Roivant Sciences (ROIV) has 6 years of EBT data on file, last reported at -$718.7 million in Q4 2025.

• Quarterly EBT fell 50.18% year-over-year to -$718.7 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was -$1.6 billion (down 136.69% YoY) and the FY2026 annual result came in at -$264.6 million, up 61.18% from the prior year.
• EBT eased to -$718.7 million in Q4 2025, from -$159.0 million in the prior quarter.
• In the past five years, EBT ranged from a high of $5.2 billion in Q4 2023 to a low of -$1.0 billion in Q4 2022.
• A 5-year average of $3.3 million and a median of -$269.3 million in 2025 frame the typical range for EBT.
• Annual changes were most pronounced in 2021 — EBT tumbled 1394.75% — and 2023, when it jumped 592.87%.
• Tracing ROIV's EBT over 5 years: stood at -$632.3 million in 2021, then slumped by 65.37% to -$1.0 billion in 2022, then jumped by 592.87% to $5.2 billion in 2023, then tumbled by 109.29% to -$478.5 million in 2024, then tumbled by 50.18% to -$718.7 million in 2025.
• The last three EBT figures came in at -$718.7 million (Q4 2025), -$159.0 million (Q3 2025), and -$269.3 million (Q2 2025), per Business Quant data.